AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 13 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States say that HIV drug resistance mutations do not yet have a significant impact on the chance of maternal transmission.
Dr. Paul Palumbo and colleagues at the University of Medicine and Dentistry of New Jersey - New Jersey Medical School in Newark, the U.S. Centers for Disease Control and Prevention and Emory University in Atlanta, Georgia, Harlem Hospital and Columbia University in New York City, and the University of Maryland School of Medicine in Baltimore evaluated the "impact of antiretroviral resistance on perinatal transmission prevention efforts."
Although they found no link between viral resistance mutations and the effectiveness of transmission prevention, Palumbo and associates warned that this situation could change rapidly.
The researchers examined 220 infected women, all of whom had undergone zidovudine (AZT) therapy, and 24 of their newborn HIV[superscript]+ children. The prevalence of viral mutations conferring AZT resistance was 17.3% in this population, they noted.
AZT resistance mutations were also found in 8.3% (2 of 23) of the infants studied, according to the report. However, the mutations seen in these children did not appear to be related to the maternal polymorphisms.
Despite the high prevalence of AZT-related mutations, viral resistance to protease inhibitors and nonnucleoside reverse ...